These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37893474)

  • 1. Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches.
    Degirmenci Y; Angelopoulou E; Georgakopoulou VE; Bougea A
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions.
    Sun C; Armstrong MJ
    Behav Sci (Basel); 2021 Apr; 11(4):. PubMed ID: 33920698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort.
    Hobson P; Meara J
    Int J Geriatr Psychiatry; 2015 Oct; 30(10):1048-55. PubMed ID: 25676160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subjective cognitive decline in idiopathic Parkinson´s disease: A systematic review.
    Oedekoven C; Egeri L; Jessen F; Wagner M; Dodel R
    Ageing Res Rev; 2022 Feb; 74():101508. PubMed ID: 34740867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current concepts in treating mild cognitive impairment in Parkinson's disease.
    Schneider JS; Kortagere S
    Neuropharmacology; 2022 Feb; 203():108880. PubMed ID: 34774549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Italian version of the Parkinson's Disease- Cognitive Functional Rating Scale.
    Garon M; Weis L; Siquier A; Fiorenzato E; Pistonesi F; Cianci V; Canesi M; Pesce F; Reali E; Pozzi B; Isaias IU; Siri C; Santangelo G; Cuoco S; Barone P; Kulisevsky J; Antonini A; Biundo R
    J Neural Transm (Vienna); 2024 Apr; 131(4):305-314. PubMed ID: 38280057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease.
    Orgeta V; McDonald KR; Poliakoff E; Hindle JV; Clare L; Leroi I
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD011961. PubMed ID: 32101639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjective cognitive decline and progression to dementia in Parkinson's disease: a long-term follow-up study.
    Galtier I; Nieto A; Lorenzo JN; Barroso J
    J Neurol; 2019 Mar; 266(3):745-754. PubMed ID: 30635723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of Visuospatial and Visuoperceptual Errors as Predictors of Dementia in Parkinson's Disease Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Galtier I; Nieto A; Mata M; Lorenzo JN; Barroso J
    J Int Neuropsychol Soc; 2021 Aug; 27(7):722-732. PubMed ID: 33303048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-Analysis of Cognition in Parkinson's Disease Mild Cognitive Impairment and Dementia Progression.
    Wallace ER; Segerstrom SC; van Horne CG; Schmitt FA; Koehl LM
    Neuropsychol Rev; 2022 Mar; 32(1):149-160. PubMed ID: 33860906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease.
    Li CH; Chen TF; Peng PL; Lin CH
    J Neurol; 2022 Dec; 269(12):6530-6543. PubMed ID: 35965282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild cognitive impairment in Parkinson's disease: Characterization and impact on quality of life according to subtype.
    Vasconcellos LFR; Pereira JS; Charchat-Fichman H; Greca D; Cruz M; Blum AL; Spitz M
    Geriatr Gerontol Int; 2019 Jun; 19(6):497-502. PubMed ID: 30912284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment.
    Jaramillo-Jimenez A; Bocanegra Y; Buriticá O; Pineda Salazar DA; Moreno Gómez L; Tobón Quintero CA; Aguirre-Acevedo DC; Sierra Castrillon M; Vasquez D; Velez-Hernandez JE; Borda MG; García-Cifuentes E; Aguillón DF; Madrigal-Zapata L; Aarsland D; Lopera F
    Rev Colomb Psiquiatr (Engl Ed); 2023; 52(4):305-313. PubMed ID: 38065663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychosocial therapy for Parkinson's-related dementia: study protocol for the INVEST randomised controlled trial.
    McCormick SA; McDonald KR; Vatter S; Orgeta V; Poliakoff E; Smith S; Silverdale MA; Fu B; Leroi I
    BMJ Open; 2017 Jun; 7(6):e016801. PubMed ID: 28630086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling Parkinson's disease cognitive phenotypes via resting-state magnetoencephalography.
    Simon OB; Rojas DC; Ghosh D; Yang X; Rogers SE; Martin CS; Holden SK; Kluger BM; Buard I
    J Neurophysiol; 2022 Jan; 127(1):279-289. PubMed ID: 34936515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changes.
    Jones JD; Uribe C; Bunch J; Thomas KR
    J Neurol; 2021 Jan; 268(1):337-345. PubMed ID: 32804281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Parkinson's disease dementia related to level I MDS PD-MCI.
    Hoogland J; Boel JA; de Bie RMA; Schmand BA; Geskus RB; Dalrymple-Alford JC; Marras C; Adler CH; Weintraub D; Junque C; Pedersen KF; Mollenhauer B; Goldman JG; Tröster AI; Burn DJ; Litvan I; Geurtsen GJ;
    Mov Disord; 2019 Mar; 34(3):430-435. PubMed ID: 30653248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analysis on the association between orthostatic hypotension and mild cognitive impairment and dementia in Parkinson's disease.
    Loureiro D; Bilbao R; Bordet S; Grasso L; Otero-Losada M; Capani F; Ponzo OJ; Perez-Lloret S
    Neurol Sci; 2023 Apr; 44(4):1211-1222. PubMed ID: 36542202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary Microbiota Is Associated with Cognitive Impairment in Parkinson's Disease Patients.
    Arikan M; Yildiz Z; Kahraman Demir T; Yilmaz NH; Sen A; Hanoglu L; Yildirim S
    Microbiol Spectr; 2022 Feb; 10(1):e0235821. PubMed ID: 35138147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.